Mangone Lucia, Marinelli Francesco, Bisceglia Isabella, Braghiroli Maria Barbara, Mastrofilippo Valentina, Cerullo Loredana, Pellegri Carlotta, Zambelli Alessandro, Aguzzoli Lorenzo, Mandato Vincenzo Dario
Epidemiology Unit, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.
Unit of Obstetrics and Gynaecology, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.
Cancers (Basel). 2022 Dec 31;15(1):299. doi: 10.3390/cancers15010299.
Ovarian cancer represents one of the most aggressive female cancers in the world, remaining a tumor with high lethality. This study aims to present how a multidisciplinary team (MDT) approach can improve the prognosis in terms of recurrence and death of patients. In total, 448 ovarian cancer cases registered in an Italian Cancer Registry between 2012 and 2020 were included. Information on age, morphology, stage, and treatment was collected. Recurrence and death rates were reported 1 and 2 years after diagnosis, comparing MDT vs. non-MDT approaches. Ninety-three percent had microscopic confirmation, and most showed cystic-mucinous morphology. In total, 50% were older than 65 years old. The distribution by stage was 17.6%, 4%, 44.9%, and 32.6% for stages I, II, III, and IV, respectively. The women followed by the MDT were 24.1%. Disease-free survival 1-year post-diagnosis, recurrences, recurrences-deaths, and deaths were 67.5%, 14.5%, 8.4%, and 9.6%, respectively, better than the non-MDT group (46.2%, 13.2%, 20.8 %, and 19.8%, respectively) (p < 0.01). The same positive results were confirmed two years after diagnosis, particularly for stages III and IV. Albeit small numbers, the study confirms a better prognosis for women managed by MDT with fewer recurrences and deaths, especially within the first 24 months of diagnosis.
卵巢癌是全球最具侵袭性的女性癌症之一，仍然是一种致死率很高的肿瘤。本研究旨在展示多学科团队（MDT）方法如何在患者复发和死亡方面改善预后。总共纳入了2012年至2020年期间在意大利癌症登记处登记的448例卵巢癌病例。收集了有关年龄、形态、分期和治疗的信息。在诊断后1年和2年报告复发率和死亡率，比较MDT与非MDT方法。93%有显微镜确诊，大多数表现为囊黏液性形态。总共50%年龄超过65岁。按分期分布，I期、II期、III期和IV期分别为17.6%、4%、44.9%和32.6%。接受MDT治疗的女性占24.1%。诊断后1年的无病生存率、复发率、复发死亡率和死亡率分别为67.5%、14.5%、8.4%和9.6%，优于非MDT组（分别为46.2%、13.2%、20.8%和19.8%）（p<0.01）。诊断后两年证实了同样的阳性结果，特别是对于III期和IV期。尽管数量较少，但该研究证实，由MDT管理的女性预后更好，复发和死亡更少，尤其是在诊断后的前24个月内。
